Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECARE: Iopamidol vs Iodixanol in Diabetic CKD Patients
NCT00782639Phase 4Terminated
- Sponsor
- Bracco Diagnostics Inc.
- Start
- Mar 2009
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of iopamidol in coronary artery disease (CAD) (2 arms), sponsored by Bracco Diagnostics Inc. Primary endpoints: Incidence of Contrast-induced Nephropathy and Baseline and Change From Baseline Measurements for Participants With CIN. Started Mar 2009; status: terminated.
02
Drugs
iopamidol
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00782639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00782639.